Western blot analysis of p-ERK and p-AKT in three angiosarcoma cell lines suggested slight increases in p-ERK with cediranib treatment and slight increases in p-AKT with effective trametinib treatment (supplemental Fig. S3), similar to what was seen in the RPPA analysis. This evidence concerns the gene AKT1 and angiosarcoma.